What is NBP's current stock price?

NBP (NovaBridge Biosciences) is currently trading at $1.77 with a market cap of $204.0M.

What sector is NovaBridge Biosciences in?

NovaBridge Biosciences (NBP) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is NBP a good stock to buy?

Analysts have a Buy consensus on NBP with a price target of $9.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

NBP NovaBridge Biosciences

Healthcare

$1.77-0.56%ClosedMarket Cap: $204.0M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.69

P/S

0.00

EV/EBITDA

-5.53

DCF Value

$0.11

FCF Yield

-0.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-3.5%

ROA

-53.4%

ROIC

-94.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q4 null	$0.00	$-4.4M	$—
FY null	$0.00	$-6.6M	$—
Q3 null	$0.00	$-6.8M	$—
Q2 null	$0.00	$-5.5M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$9.00

Target (Median)

$9.00

Target Range

$9.00 - $9.00

0 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-04-08

HC Wainwright & Co.Buy

2026-02-06

BTIGBuy

2025-10-24

BTIGBuy

2025-09-10

NeedhamBuy

2025-09-08

Trading Activity

Insider Trades

View All

Cao Sean Wuxiongdirector, officer: See Remarks

SellMon May 18

Hagler Mark Arnoldofficer: See Remarks

BuyTue Apr 28

Hagler Mark Arnold

SellWed Apr 22

Xu Cong Claireofficer: See Remarks

SellFri Apr 10

Yang Conor Chia-hungdirector

SellWed Apr 01

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.56

NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

Peers

ALT